Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;10(Suppl 21):S2437-S2450.
doi: 10.21037/jtd.2018.01.155.

Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer

Affiliations
Review

Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer

Jason K Molitoris et al. J Thorac Dis. 2018 Aug.

Abstract

The development of advanced radiation technologies, including intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and proton therapy, has resulted in increasingly conformal radiation treatments. Recent evidence for the importance of minimizing dose to normal critical structures including the heart and lungs has led to incorporation of these advanced treatment modalities into radiation therapy (RT) for non-small cell lung cancer (NSCLC). While such technologies have allowed for improved dose delivery, implementation requires improved target accuracy with treatments, placing increasing importance on evaluating tumor motion at the time of planning and verifying tumor position at the time of treatment. In this review article, we describe issues and updates related both to motion management and image guidance in the treatment of NSCLC.

Keywords: Radiation; carcinoma, non-small cell lung cancer (NSCLC); image guidance; motion management; proton therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Coronal CT images of a patient with newly diagnosed LA-NSCLC planned for concurrent chemoradiotherapy. (A) CT simulation with delineation of ITV (orange), CTV (red), and PTV (green); (B) CBCT performed at the time of first treatment with overlaid target volumes from simulation with interval lung collapse and associated shifting of the target volumes.
Figure 2
Figure 2
Coronal (A,B) and sagittal (C,D) CT images of a patient planned for pencil beam scanning proton therapy for newly diagnosed LA-NSCLC. (A,C) CT simulation with delineation of GTV (thin red line) and radiation isodose lines (red: 100%, blue: 95%, purple: 90%, light blue: 75%, brown: 50%); (B,D) weekly quality assurance CT scan demonstrating consolidation and under-coverage of the superior aspect of initial target volume (arrow). For reference the original ITV location is outlined (thin pink line).

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30. 10.3322/caac.21387 - DOI - PubMed
    1. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-99. 10.1016/S1470-2045(14)71207-0 - DOI - PMC - PubMed
    1. Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage III Non–Small-cell lung cancer: Pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387-94. 10.1200/JCO.2016.70.0229 - DOI - PMC - PubMed
    1. Speirs CK, DeWees TA, Rehman S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non–small cell lung cancer. J Thorac Oncol 2017;12:293-301. 10.1016/j.jtho.2016.09.134 - DOI - PubMed
    1. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non–small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35:56-62. 10.1200/JCO.2016.69.1378 - DOI - PMC - PubMed

LinkOut - more resources